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London and Oxford, United Kingdom; and Rome, ItalyOBJECTIVES The aims of the study were to explore the ability of native myocardial T1 mapping by
cardiac magnetic resonance to: 1) detect cardiac involvement in patients with transthyretin amyloidosis
(ATTR amyloidosis); 2) track the cardiac amyloid burden; and 3) detect early disease.
BACKGROUND ATTR amyloidosis is an underdiagnosed cause of heart failure, with no truly quan-
titative test. In cardiac immunoglobulin light-chain amyloidosis (AL amyloidosis), T1 has high diagnostic
accuracy and tracks disease. Here, the diagnostic role of native T1 mapping in the other key type of car-
diac amyloid, ATTR amyloidosis, is assessed.
METHODS A total of 3 groups were studied: ATTR amyloid patients (n ¼ 85; 70 males, age 73  10
years); healthy individuals with transthyretin mutations in whom standard cardiac investigations were
normal (n ¼ 8; 3 males, age 47  6 years); and AL amyloid patients (n ¼ 79; 55 males, age 62  10 years).
These were compared with 52 healthy volunteers and 46 patients with hypertrophic cardiomyopathy
(HCM). All underwent T1 mapping (shortened modiﬁed look-locker inversion recovery); ATTR patients
and mutation carriers also underwent cardiac 3,3-diphosphono-1,2-propanodicarboxylicacid (DPD)
scintigraphy.
RESULTS T1 was elevated in ATTR patients compared with HCM and normal subjects (1,097  43 ms
vs. 1,026  64 ms vs. 967  34 ms, respectively; both p < 0.0001). In established cardiac ATTR amyloid-
osis, T1 elevation was not as high as in AL amyloidosis (AL 1,130  68 ms; p ¼ 0.01). Diagnostic perfor-
mance was similar for AL and ATTR amyloid (vs. HCM: AL area under the curve 0.84 [95% conﬁdence
interval: 0.76 to 0.92]; ATTR area under the curve 0.85 [95% conﬁdence interval: 0.77 to 0.92];
p < 0.0001). T1 tracked cardiac amyloid burden as determined semiquantitatively by DPD scintigraphy
(p < 0.0001). T1 was not elevated in mutation carriers (952  35 ms) but was in isolated DPD grade 1
(n ¼ 9, 1,037  60 ms; p ¼ 0.001).
CONCLUSIONS Native myocardial T1 mapping detects cardiac ATTR amyloid with similar diagnostic
performance and disease tracking to AL amyloid, but with lower maximal T1 elevation, and appears to be
an early disease marker. (J Am Coll Cardiol Img 2014;7:157–65) ª 2014 by the American College of
Cardiology Foundation
TA B B R E V I A T I O N S
A N D A C R O N YM S
AL amyloidosis =
immunoglobulin light-chai
amyloidosis
ATTR amyloidosis =
transthyretin amyloidosis
CMR = cardiac magnetic
resonance
DPD = 3,3-diphosphono-1,
2-propanodicarboxylicacid
ECG = electrocardiogram
HCM = hypertrophic
cardiomyopathy
LGE = late gadolinium
enhancement
LV = left ventricle/ventricu
LVH = left ventricular
hypertrophy
NT-proBNP = N-terminal p
brain natriuretic peptide
RV = right ventricle/ventric
ShMOLLI = shortened mod
look-locker inversion recov
TTR = transthyretin protein
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158wo types of amyloidosis typically inﬁltrate the notably 3,3-diphosphono-1,2-propanodicarboxylicacid
ventricular myocardium: immunoglobulin
light-chain (AL, or primary systemic) type
and transthyretin (ATTR) type. ATTR en-
compasses senile systemic amyloidosis, in which
wild-type transthyretin (TTR) is deposited as am-
yloid, and hereditary forms, in which genetically
variant forms of TTR are implicated. Some TTRSee page 166variants affect mainly the heart (familial amyloid
cardiomyopathy); others mainly the peripheral and
autonomic nervous systems in addition to the heart
(familial amyloid polyneuropathy). Cardiac ATTRFrom *The H
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eryamyloidosis is a progressive and often fatal
disorder that may be greatly under-
diagnosed and is certainly an underap-
preciated cause of heart failure in the
elderly and speciﬁc ethnic populations.
ATTR amyloid deposits are present in 8%
to 16% of hearts at autopsy in those over
age 80 years (1). One particular TTR
variant, V122I, which confers susceptibil-
ity to amyloid cardiomyopathy, has a
population prevalence of 3% to 4% in
Afro-Caribbeans (2) and a 10% frequency
among individuals of this ethnicity who
present with heart failure (3).
Diagnosing cardiac ATTR amyloidosis
is often challenging. A suggestive con-
stellation of electrocardiography (ECG),
echocardiography, and biomarker ﬁndings
are found mainly in advanced disease, but
interpretation may be confounded by
common comorbidities such as left ven-
tricular hypertrophy (LVH), diabetes,
diastolic dysfunction, and renal disease
(4–6). The challenging diagnosis and lackof validated quantitative investigations to monitor
the course of the disease pose unique problems at a
time when new speciﬁc therapies for ATTR
amyloidosis are emerging (7).
New imaging modalities are, however, showing
promise. Technetium-labeled bone scintigraphy tracers,eart Hospital, London, United Kingdom; yInstitute of Cardiov
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ATTR amyloid (8), whereas cardiac magnetic reso-
nance (CMR) late gadolinium enhancement (LGE)
produces a characteristic appearance (9). However,
neither is truly quantitative, and both have limitations
(10).
Recently, native myocardial T1 mapping has been
shown in cardiac AL amyloid to track disease (11).
Here, we assess this test in patients with ATTR
amyloidosis. We hypothesized that the native
myocardial T1 would be elevated in this disease,
that elevation would correlate with other disease
markers (e.g., intensity of DPD uptake), and that
T1 elevation would be an early marker of disease.
METHODS
Amyloidosis patients. Subjects were recruited at the
National Amyloidosis Centre, Royal Free Hospital,
London,UnitedKingdom, from2010 to 2013.A total
of 172 individuals were categorized into 3 groups.
ATTR AMYLOID PATIENTS. Eighty-ﬁve consecutive,
consenting patients with cardiac ATTR amyloidosis
(70 male; age 73  10 years) were recruited. The
presence of cardiac amyloid was deﬁned by presence
of ATTR amyloid in a myocardial biopsy or positive
DPD scintigraphy. A total of 82% (n ¼ 70) had
histological proof of ATTR amyloidosis by Congo
red and immunohistochemical staining of myocar-
dial (n ¼ 30, 35%) or other tissues (n ¼ 40, 47%).
All patients underwent sequencing of exons 2, 3,
and 4 of the TTR gene. No consensus criteria exist
for deﬁnite cardiac involvement in ATTR amyloid
patients, and in this study, deﬁnite cardiac ATTR
amyloid was deﬁned as: 1) cardiac biopsy showing
ATTR amyloid; 2) noncardiac biopsy showing
ATTR amyloid in association with LV/right ven-
tricular (RV) thickening in the absence of other
explanatory causes; 3) intense DPD uptake in heart
(grade 2 or 3 as deﬁned by Perugini et al. [8]) in the
absence of a plasma cell dyscrasia; or 4) noncardiac
biopsy showing presence of ATTR amyloid and
LGE consistent with cardiac amyloid. In practice,ascular Science, University College London, London, United
on, United Kingdom; xDepartment of Cardiovascular, Res-
University of Rome, Rome, Italy; and the kDivision of Car-
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grant funding from GlaxoSmithKline. All other authors have
r to disclose.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 2 , 2 0 1 4 Fontana et al.
F E B R U A R Y 2 0 1 4 : 1 5 7 – 6 5 Native T1 Mapping in ATTR Amyloidosis
159all had apparent LVH. Possible cardiac involvement
was deﬁned by minimal cardiac DPD uptake (grade
1 as deﬁned by Perugini et al. [8]) in the absence of
LVH; in practice, none of these patients had LVH.
TTR GENE CARRIERS. There were 8 TTR gene
carriers (n ¼ 8; 3 male, age 47  6 years), deﬁned as
individuals with pathogenic TTR gene mutation but
no evidence of disease (no cardiac uptake on
technetium-99m [99mTc]-DPD scintigraphy and
normal echocardiography, CMR, N-terminal pro-
brain natriuretic peptide [NT-proBNP], and tro-
ponin T). This group constituted the noncardiac
involvement group.
AL AMYLOID PATIENTS. There were 79 patients
with systemic AL amyloid (55 male; age 62  10
years), as proven with biopsies from the myocar-
dium (n ¼ 6, 8%) or other tissues (n ¼ 73, 92%).
Cardiac categorization was based on international
consensus criteria (12) but with an additional
“possible involvement” category. Categorization was
deﬁned as: 1) deﬁnite cardiac involvement: LV wall
thickness of >12 mm in the absence of any other
known cause or RV free wall thickening coexisting
with LV thickening in the absence of systemic or
pulmonary hypertension; 2) possible cardiac
involvement: LV wall thickening in the presence of
hypertension; RV thickening in the presence of
pulmonary hypertension or normal wall thickness
with diastolic dysfunction and raised serum bio-
markers; and 3) no suspected involvement: normal
wall thickness with normal serum biomarkers.
These 3 groups were compared with 46 patients
with hypertrophic cardiomyopathy (HCM) and 52
healthy volunteers.
HCM patients. There were 46 patients with HCM
(n ¼ 46; age 50  13 years, 34 male) fulﬁlling
diagnostic criteria (13). A total of 72% of patients
had an asymmetrical septal hypertrophy pattern (the
remainder had apical predominant hypertrophy);
60% had LV outﬂow tract obstruction; and 76%
were found to have LGE in a variety of locations,
such as at the RV insertion points or the LV apex.
Healthy volunteers. A total of 52 healthy volunteers
(n ¼ 52; age 46  15 years, 17 male) were recruited
through advertising in hospitals, universities, and
general practitioner surgeries. All had no history or
symptoms of cardiovascular disease or diabetes
mellitus, and all had normal 12-lead ECG and
normal CMR scan. No patient was on cardioactive
medication, except for 4 patients on statins for
primary prevention.
All patients and healthy controls underwent
12-lead ECG. Cardiac amyloid patients/carriersadditionally underwent assays of cardiac biomarkers
(NT-proBNP and troponin T), echocardiography,
and a 6-min walk test when health and patient
choice permitted (e.g., test was not undertaken
when prohibited by arthritis, postural hypotension,
or neuropathy). The ATTR group also underwent
DPD scintigraphy. The baseline characteristics of
all patients are provided in Table 1. All ethics were
approved by the UCL/UCLH Joint Committees on
the Ethics of Human Research Committee.
Exclusion criteria. All patientswith contraindications
to CMR (i.e., glomerular ﬁltration rate<30 ml/min,
incompatible devices) were excluded from the study.
CMR protocol. All subjects underwent standard
CMR on a 1.5-T clinical scanner (Avanto, Siemens
Healthcare, Erlangen, Germany). A standard vol-
ume and LGE study was performed (14). The
contrast agent was 0.1mmol/kg of gadolinium-based
contrast (gadoterate meglumine [Dotarem, Guerbet
SA, Paris, France]) with 5-min delay, and the LGE
sequence was either a standard fast low-angle single
shot inversion recovery or true fast imaging with
steady state free precession sequence, with a phase
sensitive inversion recovery sequence or magnitude
reconstruction. For native T1 mapping, basal and
midventricular short-axis and 4-chamber long-axis
views were acquired using the shortened modi-
ﬁed look-locker inversion recovery (ShMOLLI)
sequence after regional shimming, as previously
described (Fig. 1) (15).
99mTc-DPD scintigraphy. Patients were scanned
using 2 GE Medical Systems (Fairﬁeld, Con-
necticut) hybrid single photon emission computed
tomography (SPECT) computed tomography (CT)
gamma cameras (Inﬁnia Hawkeye 4 and Discovery
670) following administration of 700 MBq of
intravenously-injected 99mTc-DPD. The 3-h
(delayed) whole body planar images were acquired,
followed by SPECT of the heart with a low-dose,
noncontrast CT scan. Gated/nongated cardiac
SPECT reconstruction and SPECT-CT image
fusion was performed on the GE Xeleris worksta-
tion. Cardiac retention of 99mTc-DPD was visually
scored as:
 Grade 0: no visible myocardial uptake in both the
delayed planar or cardiac SPECT-CT scan;
 Grade 1: cardiac uptake on SPECT-CT only or
cardiac uptake of less intensity than the accom-
panying normal bone distribution;
 Grade 2: moderate cardiac uptake with some
attenuation of bone signal; and
 Grade 3: strong cardiac uptake with little or no
bone uptake.
Figure 1.
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Table 1. Baseline Characteristics of Patients and Healthy Controls
TTR Mutation Carriers
(n [ 8)
Possible
ATTR
(n [ 9)
Deﬁnite ATTR
(n [ 76)
Deﬁnite
AL
(n [ 45)
HCM
(n [ 46)
Healthy Controls
(n [ 52)
Men/women 3/5 3/6 68/8 33/12 34/12 17/35
Age, yrs 47  6 67  15 73  9 63  9 50  13 46  15
Afro-Caribbean 0 1 24 2 3 1
eGFR, ml/min/1.73 m2 82  14 82  15 62  19 74  20 66  7 92  16
NT-proBNP, pmol/l 7.5 (4.7–9.7) 14 (10–85) 286 (165–524) 194 (160–457) 66 (19–114) d
AF/atrial ﬂutter, % 0 0 33 11 2 0
CMR indexes
EDVi, ml/m
2 67  13 61  9 70  15 62  16 68  14 73  12
ESVi, ml/m
2 21  8 20  12 33  15 24  9 17  9 25  7
LVEF, % 69  7 69  15 53  15 61  11 75  8 67  6
SVi, ml/m
2 46  7 41  6 36  9 38  12 51  9 48  15
LV massi, g/m
2 60  11 74  18 133  27 101  25 129  42 65  6
LAAi, cm
2/m2 13  2 12  3 16  3 14  3 15  5 11  1
Values are n, mean  SD, or median (interquartile range).
AF ¼ atrial ﬁbrillation; AL ¼ light-chain amyloidosis; ATTR ¼ transthyretin amyloidosis; CMR ¼ cardiac magnetic resonance; EDVi ¼ end-diastolic volume indexed;
ESVi ¼ end-systolic volume indexed; eGFR ¼ estimated glomerular ﬁltration rate; LV ¼ left ventricular; LAAi ¼ left atrial area indexed; NT-proBNP ¼ N-terminal pro-
brain natriuretic peptide; LVEF ¼ left ventricular ejection fraction; SVi ¼ stroke volume indexed; TTR ¼ transthyretin protein.
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160CMR image analysis. All CMR images and maps
were analyzed ofﬂine. For T1 measurements, the
basal ventricular short-axis or the 4-chamber
ShMOLLI image was manually contoured app-
roximately 2 pixels in (to minimize partial volume
effects) from the endocardium and epicardium, and
the average T1 value was calculated (Fig. 1). This
was drawn without review of the LGE images. The
LGE images were visually analyzed for the presence
or absence of enhancement, blinded to T1 mapping
results. The presence of LGE was classiﬁed as:
circumferential in the subendocardium; diffuseExamples of ROIs in ShMOLLI
ntrast 4-chamber and (B) pre-contrast short-axis shortened modiﬁed
r inversion recovery (ShMOLLI) image with regions of interest (ROIs)
the basal septum of the left ventricle for native myocardial T1.circumferential (extend into the epicardial layer);
and abnormal contrast handling on T1 scout with
no discernible LGE.
Statistical analysis. Statistical analysis was per-
formed using IBM SPSS Statistics version 19 (IBM,
Somers, New York). All continuous variables were
normally distributed (Shapiro-Wilk) other than
NT-proBNP and troponin T, which were there-
fore log-transformed for bivariate testing; these are
presented as mean  SD, with nontransformed
NT-proBNP presented as median and interquartile
range. Comparisons between groups were performed
by 1-way analysis of variance with post-hoc Bon-
ferroni correction. The chi-square test or Fisher
exact test was used to compare discrete data as
appropriate. Receiver-operating characteristic (ROC)
curve analysis was performed to deﬁne the diagnostic
accuracy of native T1. Correlation between contin-
uous variables was assessed using Pearson’s r corre-
lation coefﬁcient. Statistical signiﬁcance was deﬁned
as p < 0.05.RESULTS
A total of 85 patients with ATTR amyloid, 8 TTR
mutation carriers and 79 patients with AL amyloid
were enrolled. These were compared with 52
healthy volunteers and 46 patients with HCM.
Baseline characteristics are shown in Table 1. Am-
yloid patients had the following comorbidities:
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161treated hypertension (22% ATTR, 15% AL); dia-
betes (12% ATTR, 3% AL); and angiographically-
conﬁrmed coronary artery disease (13% ATTR, 9%
AL). The echocardiogram was performed within
1 day of the CMR. The time gap between the DPD
and CMR was 26  36 days. Thirty-ﬁve ATTR
amyloid patients were familial (V122I [n ¼ 18],
T60A [n ¼ 6], V30M [n ¼ 2], and E54G [n ¼ 2],
and all others unique: D38Y, G47V, E89K, I84S,
I107F, L12P, and S77Y); 50 had senile systemic
amyloidosis (SSA). Of the 8 gene carriers, 5 had
TTR V30M and 3 had T60A. Compared with
deﬁnite cardiac AL patients, deﬁnite ATTR amy-
loid patients had a higher LV mass index (133  27
vs. 101  25) and reduced ejection fraction (53 
15% vs. 61  11%). The PR interval and QRS were
longer in ATTR (PR 209  54 ms vs. 185  38 ms,
QRS 116  28 ms vs. 106  23 ms; both p < 0.05).
The NT-proBNP and troponin T biomarker con-
centrations were similar.
T1 elevation. T1 was elevated in ATTR patients
compared with HCM and normal subjects (1,097 
43 ms vs. 1,026  64 ms vs. 967  34 ms; both p <
0.0001). In established disease, ATTR T1 elevation
was not as high as in AL (AL 1,130  68 ms; p ¼
0.01). T1 was not elevated in mutation carriers (952
 35 ms) (Figs. 2 and 3).Figure 2. Characteristic Examples From CMR Scans
CMR end-diastolic cine still (top), shortened modiﬁed look-locker inver
enhancement (LGE) images (bottom) in (left to right) healthy volunte
light-chain amyloidosis (AL amyloidosis), and deﬁnite transthyretin amyT1 diagnostic accuracy. The ROC curve analysis
was performed for the discrimination of possible
or deﬁnite cardiac amyloid from the meaningful
combined differentials of HCM, systemic amyloid
without detected cardiac involvement, or ATTR
mutation-positive patients without evidence of car-
diac amyloid. Using ROC analysis, ATTR and
AL amyloid patients with possible or deﬁnite car-
diac involvement had an area under the receiver-
operating characteristic curve (AUC) of 0.85 (95%
conﬁdence interval [CI]: 0.79 to 0.92).
Example cut-off values to diagnose cardiac amy-
loid (high speciﬁcity) are 1,048 ms, 1,065 ms, and
1,090 ms. These values have 80%, 85%, and 90%
speciﬁcity and 83%, 74%, and 56% sensitivity,
respectively. Example cut-off values to rule out
cardiac amyloid (high sensitivity) are 954 ms, 968 ms,
and 1,012 ms. These values have 99%, 98%, and 95%
sensitivity and 17%, 30%, and 58% speciﬁcity,
respectively. Native T1 was similarly accurate for AL
and ATTR (AUC: 0.84, 95% CI: 0.76 to 0.91 and
AUC 0.85, 95% CI: 0.77 to 0.92, respectively)
(Fig. 4).
T1 and DPD/LGE ﬁndings. T1 increased with
increasing cardiac amyloid burden, as assessed by
bone scintigraphy (p < 0.0001 for trend) (Fig. 5).
T1 was not elevated in mutation carriers (952 35 ms)sion recovery native T1 map (middle), and late gadolinium
er, hypertrophic cardiomyopathy (HCM), deﬁnite immunoglobulin
loidosis (ATTR amyloidosis) patients.
Figure 3. Native T1 in Healthy Volunteers, Mutation Carriers, HCM,
Deﬁnite AL, and Deﬁnite ATTR
Mean native myocardial T1  2 SE in healthy control subjects, gene carriers,
patients with deﬁnite AL cardiac amyloidosis, and patients with deﬁnite ATTR
cardiac amyloidosis. Abbreviations as in Figure 2.
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162but was elevated in the 9 patients with isolated
DPD grade 1 (1,037  60 ms, p ¼ 0.001), all of
which had no amyloid-like LGE (but 1 had inferior
myocardial infarction and 1 had RV LGE).
T1 and cardiac function, biomarkers, ECG, and 6-min
walk test. Correlations were broadly similar for AL
and ATTR disease (Table 2). T1 correlated with
indexes of systolic and diastolic function, indexed
LV mass, and known prognostic biomarkers bothA B
Figure 4. ROC Curve for Native T1
Receiver operating characteristic (ROC) curve for the discrimination of p
clinically signiﬁcant differentials of HCM. Systemic amyloid without dete
apparent cardiac amyloid for: (A) cardiac amyloid, type unspeciﬁed (AL
AUC¼ area under the curve; CI ¼ conﬁdence interval; other abbreviatioin ATTR and AL amyloid patients. In ATTR
patients, T1 correlated with indexed left atrial area,
6-min walk test performance, and PR and QRS
duration on ECG, whereas in AL patients, T1
correlated with indexed stroke volume, ECG, limb
lead mean voltage, and E deceleration time
(Table 2).
D I SCUSS ION
In this, the largest ever CMR study in patients with
amyloidosis, we found that native myocardial T1
mapping has a high diagnostic accuracy for cardiac
amyloid for both AL and ATTR when compared
against HCM, a relevant clinical differential diag-
nosis. Furthermore, T1 tracks cardiac amyloid bur-
den in both diseases, and is more sensitive for
detecting early disease in gene mutation carriers than
LGE imaging. In both amyloid types, T1 tracks
markers of systolic and diastolic function, mass, and
prognostic markers. In ATTR amyloid, T1 addi-
tionally correlates with ECG PR and QRS duration
and indexed left atrial area, whereas in AL type, it
correlates with reductions in limb lead voltages. T1
also has functional associations with a reduction in
6-min walk test in ATTR amyloidosis. Interestingly
and perhaps unexpectedly (16), T1 elevation was
lower in ATTR compared with AL type.
Amyloidosis is considered the exemplar of an
interstitial disease, as the quantity of amyloid in the
extracellular space amounts to kilograms overall inC
ossible or deﬁnite cardiac amyloid by native myocardial T1 from the
cted cardiac involvement or ATTR mutation-positive patients without
and ATTR); (B) AL amyloid alone; or (C) ATTR amyloid alone.
ns as in Figure 2.
Figure 5. Native T1 and DPD Grade
Mean native myocardial T1  2 SE in gene carriers and ATTR patients
according to different degrees of uptake on the technetium-99m
3,3-diphosphono-1,2-propanodicarboxylicacid (DPD) scintigraphy.
Table 2. Correlations Between T1 and Cardiac Function, Biomarkers,
ECG, and 6-Min Walk Test in ATTR and AL Patients
ATTR Patients AL Patients
LV structure by CMR
LV massi, g/m
2 0.62* 0.44*
LA areai, cm
2/m2 0.31* 0.058
LV systolic function by CMR
LVEF, % 0.22* 0.36*
SVi, ml/m
2 0.151 0.28y
LV diastolic function by echocardiogram
E/E0 0.32* 0.47*
E-deceleration time, ms 0.106 0.41*
6-min walking test 0.32 0.147
Biomarkers
NT-proBNP, pmol/l 0.57* 0.56*
Troponin T, pmol/l 0.57* 0.32y
ECG
PR, ms 0.32y 0.073
QRS, ms 0.26y 0.077
ECG limb lead mean voltage, mm 0.151 0.48*
Values are Pearson’s r correlation coefﬁcient. *p < 0.01. yp < 0.05.
ECG ¼ electrocardiogram; other abbreviations as in Table 1.
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163some patients and is able to constitute the majority
of the heart by weight at times (17).
Our earlier work in AL amyloidosis demon-
strated that measurement of myocardial T1 times
using ShMOLLI had high diagnostic accuracy
(against aortic stenosis) and tracks disease burden
(11). Here, this work is extended to ATTR, and the
diagnostic accuracy was tested against hypertrophic
cardiomyopathy, a relevant clinical differential.
Although T1 was raised in the ATTR amyloid, it
was not as high as in AL type, a surprising ﬁnding
given that ventricular wall thickness is greater in
ATTR amyloid (16). T1 mapping measures a
composite tissue signal from both cells and the
interstitium. The extent and/or distribution of am-
yloid, plus how it interacts with water or changes in
the myocyte signal, could all be implicated in
causing the T1 difference. Therefore, the less raised
T1 value found in patients with ATTR amyloidosis
could be due to (amongst others), a lower amyloid
burden, less hydration of the amyloid, less collagen
associated with amyloid, or differential effects on
the intracellular signal. Finally, AL may have
additional processes occurring, such as edema from
possible light chain toxicity (18,19). Further work is
needed. Many differences in the biology of ATTR
and AL cardiac amyloidosis have been described but
are not understood. This study shows speciﬁc dif-
ferences between AL and ATTR in their correla-
tions with other parameters; for example, the
positive correlations in ATTR amyloid of T1 with
left atrial area, PR, and QRS duration, and the
negative correlations in AL amyloid of T1 with
mean QRS voltage in the limb leads. These ﬁndings
support the concept that ATTR amyloid may be a
more purely inﬁltrative disease, whereas AL may
have a dual pathology with contributions from
interstitial expansion and cell death.
Native myocardial T1 yielded high diagnostic
accuracy in ATTR and AL amyloidosis against the
common clinical differential diagnosis of HCM.
These ﬁndings combine a number of key advan-
tages of the mapping technique: the absence of need
for contrast, a single breath-hold per T1 map,
simple analysis, and the potential for measurement
of whole-heart T1. Other investigators have pro-
posed bone scintigraphy using the DPD tracer as
the noninvasive “gold standard” for diagnosis of
cardiac ATTR amyloid (20). However, this is
semiquantitative and is scored in 4 grades based on
visual estimation; although the radiation dose is
low, serial follow-up is problematic for gene mu-
tation carriers. Native T1 showed high concordance
with DPD scintigraphy, and T1 was measured ona continuous scale, which is a possible advantage.
DPD scanning dichotomizes mutation carriers in-
to DPD negative or DPD grade 1. T1 was exactly
concordant with this dichotomy, with T1 ele-
vation and DPD grade 1 patients having no other
abnormalities (no hypertrophy, no biomarker
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164elevation, and no amyloid-related LGE), suggesting
that both methods identify the earliest disease
expression. These preliminary ﬁndings require
further conﬁrmation in larger, particularly multi-
center, studies with assessment of diagnostic and
prognostic performance. In native T1 measurement,
there is the potential for age and sex biases. Some of
these biases may be about partial voluming and may
have reduced relevance in hypertrophied hearts.
The disease biology means that the ATTR and AL
populations have a different age of presentation,
with ATTR patients being older and more often
male. The HCM patients and the controls are
younger. Data on age-dependent changes in T1 are
conﬂicting. A subtle trend in increasing T1 mea-
surement has been detected in MESA (Multi-
Ethnic Study of Atherosclerosis) (r2 ¼ 0.021, 5 ms/
decade in men but not women [21]), but there was
a reduction in T1 with age in women but not men
with ShMOLLI (22). Fortunately, most of the ef-
fect sizes detected here are large compared to the
potential biases, and some of them are in the
opposite direction of a confounding bias: for
example, the (10 years younger) AL patients have
more T1 elevation than the ATTR patients by
33 ms, which is the opposite of the age-related bias
that most experts expect to exist. The ATTR
patients were 82% male, whereas the AL popula-
tion was 72% male. A male/female difference in T1
was not found in patients over age 45 years in the
paper by Piechnik et al. (22), but even if a 24 ms
difference was found in the young males versus
females, this would make only a w3 ms overall
difference, w10% of the difference found in this
paper. Furthermore, ATTR patients more often
had hypertension, coronary artery disease, and dia-
betes. All of these factors might be expected to
contribute to an increase in T1 times in ATTR
patientsdthe opposite trend to that found, which
could potentially lead to an underestimation of the
difference between AL and ATTR patients.
Study limitations. The main limitation of this study
is the lack of histological validation of the technique.
This is challenging because diagnosis in manypatients was secured through biopsy of noncardiac
sites, and it was not ethical to obtain cardiac biopsies
for research given its invasive nature. Furthermore,
quantiﬁcation of amyloid (rather than presence/
absence) is challenging in myocardial biopsies due to
its often patchy and microscopic distribution. The
second limitation is lack of biopsy evidence of am-
yloid in 18% of ATTR patients. However, this
cohort of patients was fully characterized with all
other clinical investigative techniques currently
available. When combined, these are known to
provide high diagnostic accuracy. CMR extracellular
volume measurement was not included in this study.
No follow-up data are available at this time. T1
mapping is yet to be standardized across manufac-
turers, although efforts are underway to do this. In
our paper, we analyzed only a single region of in-
terest in the septum. A segmental or whole-heart
approach should be explored in the future.
CONCLUS IONS
Native myocardial T1 mapping detects cardiac
ATTR amyloid and has similar performance for
diagnosis and tracking disease in both ATTR and
AL amyloidosis. The lower T1 elevation in ATTR
amyloid, and the speciﬁc differences between AL
and ATTR correlations with other cardiac ﬁndings,
may support a concept of ATTR amyloid as a more
purely inﬁltrative disease, whereas the AL type may
have a dual pathology with both interstitial expan-
sion and cell death.
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